As well, the effects of erythropoietin (EPO)—given to MDS patients to combat anemia and defer blood transfusions—are suppressed by TNF-a, and it has been found that giving lenalidomide with EPO improves this unwanted suppressive effect [80,81]. Here, EPO is linked to myelodysplastic syndrome.